Trial Profile
A Randomized, Controlled, Multicenter, Open-label Study With Blinded Assessment of the Efficacy of Subcutaneous Secukinumab Compared to Fumaderm in Adults With Moderate to Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary) ; Calcium monoethyl fumarate/dimethyl fumarate/magnesium monoethyl fumarate/zinc monoethyl fumarate
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms PRIME
- Sponsors Novartis; Novartis Pharmaceuticals
- 21 Sep 2016 Status changed from recruiting to completed.
- 19 Jun 2015 New trial record